Adding saxagliptin to metformin extended release (XR) or uptitration of metformin XR: Efficacy on daily glucose measures

Diabetes Therapy

Volumn 4, Issue 2, 2013, Pages 269-283

  Neutel, Joel M ^a   Zhao, Cathy ^b   Karyekar, Chetan S ^b  

^a Orange County Research Center   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Efficacy; Glycemic control; Metformin; Saxagliptin; Tolerability; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; SAXAGLIPTIN;

ADULT; AGED; ARTICLE; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; UPPER ABDOMINAL PAIN;

EID: 84893759578     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-013-0028-9     Document Type: Article

References (24)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59.
3. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295:1681-7.
4. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-8.
5. Brick JC, Derr RL, Saudek CD. A randomized comparison of the terms estimated average glucose versus hemoglobin A1C. Diabetes Educ. 2009;35:596-602.
6. Bode BW. Defining the importance of daily glycemic control and implications for type 2 diabetes management. Postgrad Med. 2009;121:82-93.
7. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-40.
8. Nichols GA, Glauber HS, Javor K, Brown JB. Achieving further glycemic control in type 2 diabetes mellitus. West J Med. 2000;173:175-9.
9. Glucophage (metformin hydrochloride) and Glucophage XR (metformine hydrochloride extended-release). Full Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
10. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16.
11. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-12.
12. Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012;14:365-71.
13. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin. 2005;21:2029-35.
14. Neumiller JJ, Campbell RK. Saxagliptin: a Dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus. Am J Health Syst Pharm. 2010;67:1515-25.
15. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199-206.
16. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929-40.
17. Ali S, Fonseca V. Saxagliptin overview: special focus on safety and adverse effects. Expert Opin Drug Saf. 2013;12:103-9.
18. Onglyza® (saxagliptin). Full prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2011.
19. Derosa G, Maffioli P. Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2011;4: 263-71.
20. Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther. 2012;14:350-64.
21. Davidson J, Howlett H. New prolonged-release metformin improves gastrointestinal tolerability. Br J Diabetes Vasc Dis. 2004;4:273-7.
22. Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin. 2010;26:2355-63.
23. Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig. 2012;32:189-202.
24. Granstrom O, Bergenheim K, McEwan P, Sennfalt K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza ®) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012;6:127-36.